Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

INTRODUCTION: Despite the development of new therapies for advanced prostate cancer, it remains the most common cause of cancer and the second leading cause of cancer death in men. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Open
Hlavní autoři: Scheinberg, Tahlia, Kench, James, Stockler, Martin, Mahon, Kate L, Sebastian, Lucille, Stricker, Phillip, Joshua, Anthony M, Woo, H, Thanigasalam, Ruban, Ahmadi, Nariman, Centenera, Margaret M, Butler, Lisa M, Horvath, Lisa G
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045211/
https://ncbi.nlm.nih.gov/pubmed/31988233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-033667
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky